| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P6179 | Dimensions Publication ID | 1051678638 |
| P356 | DOI | 10.1186/1471-2377-10-104 |
| P932 | PMC publication ID | 2989949 |
| P698 | PubMed publication ID | 21040531 |
| P5875 | ResearchGate publication ID | 47643833 |
| P50 | author | Sally E. Thompson | Q42283008 |
| Ian C. Marschner | Q63285438 | ||
| P2093 | author name string | Philippa Delahoy | |
| P2860 | cites work | Pregabalin add-on for drug-resistant partial epilepsy | Q24242802 |
| If we're so different, why do we keep overlapping? When 1 plus 1 doesn't make 2 | Q24548402 | ||
| Early identification of refractory epilepsy | Q28144133 | ||
| What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes | Q29615705 | ||
| The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials | Q29619501 | ||
| Gabapentin for drug-resistant partial epilepsy | Q30868274 | ||
| Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. | Q31156955 | ||
| Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 | ||
| New anti-epileptic drugs | Q34119473 | ||
| Drug treatment of partial epilepsy | Q35900135 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons | Q37167644 | ||
| Tutorial in biostatistics. Designing studies for dose response | Q41007890 | ||
| Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition | Q43922011 | ||
| Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures | Q44456515 | ||
| Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures | Q44704337 | ||
| Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy | Q45256304 | ||
| Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study | Q46879499 | ||
| Double-blind study of Gabapentin in the treatment of partial seizures | Q48903552 | ||
| Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs | Q50158883 | ||
| Gabapentin in partial epilepsy. UK Gabapentin Study Group | Q68089419 | ||
| A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma | Q70618602 | ||
| Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group | Q72180177 | ||
| Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5 | Q72586547 | ||
| Validity of indirect comparisons in meta-analysis | Q79676362 | ||
| Overview of evaluation and treatment guidelines for epilepsy | Q84065920 | ||
| P921 | main subject | gabapentin | Q410352 |
| meta-analysis | Q815382 | ||
| P304 | page(s) | 104 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | BMC Neurology | Q15763734 |
| P1476 | title | Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships | |
| P478 | volume | 10 |
| Q57790206 | A systematic survey shows that reporting and handling of missing outcome data in networks of interventions is poor |
| Q38877302 | Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. |
| Q87857518 | Conversion of Pregabalin to 4-Isobutylpyrrolidone-2 |
| Q44252190 | Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients |
| Q37999052 | Drug safety evaluation of pregabalin |
| Q47171751 | Effects of Soluble Corn Fiber Alone or in Synbiotic Combination with Lactobacillus rhamnosus GG and the Pilus-Deficient Derivative GG-PB12 on Fecal Microbiota, Metabolism, and Markers of Immune Function: A Randomized, Double-Blind, Placebo-Controlle |
| Q36845975 | Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers |
| Q84884100 | Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial |
| Q35686045 | Gabapentin: An update of its pharmacological properties and therapeutic use in epilepsy |
| Q97540059 | Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis |
| Q38064486 | Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy |
| Q38152329 | Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment |
| Q83554414 | Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second |
| Q35225090 | Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response |
| Q33949565 | Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain |
Search more.